Onlikon announced that the company signed a “Comprehensive Cooperation Agreement on Innovative Drugs and Delivery Systems” with Suzhou Ruizhijie and MicroX to develop project cooperation on three innovative drug pipelines, and plan to establish long-term strategic partnerships in the fields of delivery technology and CDMO. The total pre-clinical R&D budget after deducting the IND application fee for the first three pipelines is estimated to be 89.5 million yuan. After the agreement comes into effect, it is estimated that an additional investment of 20.5 million yuan in PCC phase R&D will be added within this year. This agreement has been approved by the company's board of directors and partner shareholders' meetings, and there is no need to submit it to the company's shareholders' meeting for review.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.